Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Expands By 56.3%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 1,668,357 shares, a growth of 56.3% from the August 15th total of 1,067,589 shares. Based on an average daily volume of 35,561,049 shares, the short-interest ratio is presently 0.0 days. Currently, 4.5% of the company’s stock are sold short.

Insiders Place Their Bets

In other Werewolf Therapeutics news, Director Luke Evnin sold 107,429 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE purchased a new position in Werewolf Therapeutics in the second quarter worth $112,000. Squarepoint Ops LLC purchased a new position in shares of Werewolf Therapeutics in the second quarter worth $37,000. Finally, BlackRock Inc. purchased a new stake in shares of Werewolf Therapeutics during the second quarter worth about $37,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

HOWL has been the topic of a number of recent research reports. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and an average target price of $4.00.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.96 on Friday. Werewolf Therapeutics has a 1 year low of $0.27 and a 1 year high of $2.38. The stock has a market capitalization of $46.90 million, a price-to-earnings ratio of -1.27 and a beta of 0.51. The company’s fifty day simple moving average is $0.63 and its two-hundred day simple moving average is $0.62.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Friday, July 31st. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.36. The company had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. Equities research analysts anticipate that Werewolf Therapeutics will post -0.89 EPS for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company uses its proprietary INDUKINE platform to design conditionally activated cytokines, which are intended to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues.

Werewolf’s pipeline has included WTX-124, an investigational interleukin-2 therapy designed to promote the expansion and activation of immune cells in tumors, and WTX-330, an investigational interleukin-12 therapy intended to activate both innate and adaptive immune responses.